Latest news and insights on the pharmaceutical industry | Indian Pharma Post | Page 267

Results For "AI"

9345 News Found

Zydus receives EIR for oncology injectable manufacturing facility in Ahmedabad SEZ1
Drug Approval | September 24, 2025

Zydus receives EIR for oncology injectable manufacturing facility in Ahmedabad SEZ1

The facility has been classified as Voluntary Action Indicated


Corning, SGD Pharma opens Rs 500 crore glass tubing facility in Telangana
News | September 24, 2025

Corning, SGD Pharma opens Rs 500 crore glass tubing facility in Telangana

Corning and SGD Pharma formed JV in June 2023 to expand pharmaceutical manufacturing in India


Glenmark signs cancer drug licensing deal with Hengrui Pharma for $18 million upfront payment
News | September 24, 2025

Glenmark signs cancer drug licensing deal with Hengrui Pharma for $18 million upfront payment

Hengrui is eligible to receive regulatory and commercial milestone payments of up to US$1.093 billion


Eli Lilly to build new $6.5 billion orforglipron manufacturing facility in Texas
News | September 24, 2025

Eli Lilly to build new $6.5 billion orforglipron manufacturing facility in Texas

The new Houston site, Lilly's eighth U.S. manufacturing facility announced since 2020, will focus on domestic production of small molecule synthetic medicines


FDA responds to evidence of possible association between autism and acetaminophen use during pregnancy
News | September 24, 2025

FDA responds to evidence of possible association between autism and acetaminophen use during pregnancy

Agency initiates safety label change and notifies physicians of possible link


Akums demonstrates clinical versatility of Lacosamide in epilepsy care
Clinical Trials | September 23, 2025

Akums demonstrates clinical versatility of Lacosamide in epilepsy care

Clinical evidence has consistently highlighted lacosamide’s efficacy and safety.


Moderna delivers Canada’s first locally manufactured mRNA vaccines
News | September 23, 2025

Moderna delivers Canada’s first locally manufactured mRNA vaccines

All drug substance for Moderna’s authorized Spikevax (COVID-19 mRNA vaccine) targeting the SARS-CoV-2 LP.8.1 variant is produced at the company’s facility in Laval, Quebec